Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2025-08-19 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
半年报监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of 普洛药业股份有限公司 regarding their 10th meeting of the 9th Supervisory Board. It includes approval of the 2025 semi-annual report text and summary, adjustments to organizational structure and company bylaws, and a mid-year profit distribution plan. The document is short (551 characters) and primarily announces decisions made at a board meeting, including that some proposals will be submitted to the shareholders' meeting. It does not contain the actual semi-annual financial report or detailed financial data, but rather the resolutions passed. Therefore, it is not the interim/quarterly report itself but an announcement of board resolutions related to such reports and other governance matters. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2025-08-19 Chinese
董事会薪酬与考核委员会工作细则
Governance Information Classification · 95% confidence The document is titled as the 'Board of Directors Remuneration and Assessment Committee Work Rules' for 普洛药业股份有限公司. It details the structure, responsibilities, and procedures of the remuneration and assessment committee under the board of directors, including how remuneration policies and assessments for directors and senior management are formulated and approved. There are no financial statements, earnings data, or regulatory filings present. The content focuses on governance practices related to remuneration and committee operations, which aligns with governance information rather than remuneration disclosure or management reports. Therefore, the document fits best under Governance Information (CGR). The document length is 2521 characters, which is relatively short but contains substantive governance content, not just an announcement or summary.
2025-08-19 Chinese
董事会秘书工作细则
Governance Information Classification · 95% confidence The document is titled as the 'Board Secretary Work Rules' for 普洛药业股份有限公司, detailing the duties, qualifications, appointment, and responsibilities of the company's board secretary. It references relevant laws and stock exchange rules but does not contain financial data, earnings, or report content. It is a governance-related document outlining internal rules and procedures for a key corporate officer role. There is no indication of it being an announcement, certification, or financial report. Therefore, it fits best under Governance Information (CGR). The document length is under 5,000 characters, but it is a substantive governance policy document, not a mere announcement.
2025-08-19 Chinese
2025年半年度财务报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "普洛药业股份有限公司2025 年半年度财务报告" which translates to "Puluo Pharmaceutical Co., Ltd. 2025 Semi-Annual Financial Report." It contains detailed financial statements including consolidated balance sheets, profit and loss statements, cash flow statements, and equity changes for the half-year period ending June 30, 2025. The report explicitly states it is a half-year report and includes comprehensive financial data and analysis for the period. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2025
2025-08-19 Chinese
半年报董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 14th meeting of the 9th Board of Directors of 普洛药业股份有限公司 (Puluo Pharmaceutical Co., Ltd.). It includes voting results on various governance matters such as adjustments to the board composition, committee structures, amendments to company bylaws, and nomination of a new director. The document also mentions that some proposals will be submitted to the shareholders' meeting for approval. The content focuses on board and management decisions and governance structure changes rather than financial results or reports. The document length is 3570 characters, which is relatively short but contains substantive information about board decisions. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management. It is not an Annual Report, Audit Report, or other financial report, nor is it a simple announcement of a report publication. Therefore, the correct classification is MANG with high confidence.
2025-08-19 Chinese
重大信息内部报告制度
Governance Information Classification · 95% confidence The document is titled as an internal reporting system for major information of 普洛药业股份有限公司 (Puluo Pharmaceutical Co., Ltd.). It details the procedures, responsibilities, and scope of reporting significant company information internally, including definitions of major information, reporting obligations, confidentiality, and management responsibilities. It references regulatory frameworks such as the Company Law, Securities Law, and Shenzhen Stock Exchange listing rules. The document is a policy or governance document outlining internal controls and reporting processes rather than a financial report, announcement, or presentation. It does not contain financial statements, earnings data, voting results, or any form of shareholder communication. It is focused on governance and compliance related to information disclosure. Therefore, the most appropriate classification is Governance Information (CGR). The document length (5752 characters) supports it being a detailed policy document rather than a brief announcement or report publication notice.
2025-08-19 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.